Price range: $29.90 through $44.90
Tesamorelin is a 44-amino-acid GHRH analogue with a trans-3-hexenoic acid modification at the N-terminus that confers resistance to DPP-4 cleavage.
Mechanism: Activates GHRH receptors to stimulate endogenous pulsatile GH release. Produces a pronounced reduction in visceral adipose tissue and improvement in lipid profile distinct from generic GH secretagogues.
Research findings: FDA-approved for HIV-associated lipodystrophy. Phase 3 trials reported 15-18% reductions in visceral adipose tissue. Subsequent research has documented reductions in hepatic fat content in HIV-NAFLD cohorts. Reference compound in visceral fat and GHRH research.
Handling: Lyophilized peptide. Store sealed at -20°C for long-term stability or 2-8°C short-term. Reconstitute with bacteriostatic water or 0.6% acetic acid as appropriate to the molecule.
COA:
✓
Lab Verified >99% purity · View lab results →
For research purposes only. Not for human consumption. This material is intended exclusively for in-vitro laboratory and preclinical research applications conducted by qualified personnel.
| Volume | 10mg, 2mg, 5mg |
|---|
Reviews
There are no reviews yet.